A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

Today's Research Daily features the Q4 earnings season scorecard and updated analyst reports on 16 major stocks, including Meta Platforms (META), Mastercard (MA) and Adobe (ADBE), as well as two micro ...

Discover a recent study that has examined the scalp microbiome in Black women diagnosed with central centrifugal cicatricial ...

The EPS beats percentage is a hair above the average for this group ... Net income of $3 million marks a turnaround from a $1.2 million prior-year loss, reflecting cost efficiencies and restructuring.

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.